<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04198948</url>
  </required_header>
  <id_info>
    <org_study_id>0101-3678/18</org_study_id>
    <secondary_id>209943/Z/17/Z</secondary_id>
    <nct_id>NCT04198948</nct_id>
  </id_info>
  <brief_title>Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers</brief_title>
  <acronym>INTERGLIKOM</acronym>
  <official_title>Interaction Between Omeprazole and Gliclazide in CYP2C19 Normal/ Ultrarapid Metabolisers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Sarajevo</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>General Hospital Prim. Dr. Abdulah Nakas</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University of Dundee</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Wellcome Trust</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Sarajevo</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Proton pump inhibitors (PPIs) are treatment of choice for different gastrointestinal&#xD;
      disorders common in type 2 diabetes. Sulfonylureas (SUs) are anti-diabetes agents&#xD;
      particularly widely used in developing countries. Gliclazide, a recommended SU drug, is&#xD;
      metabolised in part by CYP2C19, the main enzyme responsible for the PPI metabolism.&#xD;
&#xD;
      A randomised, placebo-controlled, two-sequence, two-period crossover study will be performed&#xD;
      to explore whether gliclazide pharmacokinetics (PK) and pharmacodynamics (PD) are altered&#xD;
      upon co-administration with omeprazole. Sixteen healthy volunteers, CYP2C19&#xD;
      extensive/ultrarapid metabolisers (EM/UM), will receive placebo or omeprazole alone for 4&#xD;
      days, and concomitantly with single dose of gliclazide on day 5. Plasma concentration of&#xD;
      gliclazide will be measured for 24 hours, and plasma glucose and insulin levels up to 12&#xD;
      hours after gliclazide administration.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">March 4, 2019</start_date>
  <completion_date type="Actual">August 5, 2019</completion_date>
  <primary_completion_date type="Actual">August 5, 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Gliclazide AUC</measure>
    <time_frame>24 hours</time_frame>
    <description>Area under the concentration-time curve (AUC) up to the last concentration measured</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Glucose</measure>
    <time_frame>12 hours</time_frame>
    <description>Change in glucose concentration - incremental area under the glucose concentration-time curve from 0 to 12 h</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin</measure>
    <time_frame>12 hours</time_frame>
    <description>Change in insulin concentration - incremental area under the insulin concentration-time curve from 0 to 12 h</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">15</enrollment>
  <condition>Diabetes Mellitus, Type 2</condition>
  <arm_group>
    <arm_group_label>Omeprazole, Then Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive 20 mg of omeprazole alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive placebo under same conditions in a cross-over manner.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo, Then Omeprazole</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive placebo alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive omeprazole under same conditions in a cross-over manner.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Omeprazole</intervention_name>
    <description>Omeprazole (20 mg) will be administered orally once daily for 5 days in one of the two treatment periods.</description>
    <arm_group_label>Omeprazole, Then Placebo</arm_group_label>
    <arm_group_label>Placebo, Then Omeprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo oral tablet</intervention_name>
    <description>Placebo will be administered orally once daily for 5 days in one of the two treatment periods.</description>
    <arm_group_label>Omeprazole, Then Placebo</arm_group_label>
    <arm_group_label>Placebo, Then Omeprazole</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gliclazide</intervention_name>
    <description>Gliclazide (40 mg) will be administered orally once, concomitantly with omeprazole or placebo on day 5.</description>
    <arm_group_label>Omeprazole, Then Placebo</arm_group_label>
    <arm_group_label>Placebo, Then Omeprazole</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Men&#xD;
&#xD;
          -  Age 18-30 years&#xD;
&#xD;
          -  Non-smokers&#xD;
&#xD;
          -  CYP2C19 extensive/ultrarapid metabolisers&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  medical history of hepatic, renal, gastrointestinal and hematologic disease or any&#xD;
             acute or chronic disease, or drug allergy to sulfonylureas or PPIs or history of drug&#xD;
             abuse&#xD;
&#xD;
          -  abnormalities in physical examination, ECG and routine clinical laboratory tests&#xD;
             (including fasting blood glucose concentration)&#xD;
&#xD;
          -  medication use during the 14 days prior and during the study period&#xD;
&#xD;
          -  grapefruit, grapefruit juice, alcohol, beverages or food containing methylxanthines&#xD;
             use during 72 h prior and during the study period&#xD;
      </textblock>
    </criteria>
    <gender>Male</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>30 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Tanja Dujic, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sarajevo</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Aida Kulo Cesic, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Sarajevo</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>General Hospital Prim. Dr. Abdulah Nakas</name>
      <address>
        <city>Sarajevo</city>
        <zip>71000</zip>
        <country>Bosnia and Herzegovina</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Bosnia and Herzegovina</country>
  </location_countries>
  <reference>
    <citation>Kalra S, Aamir AH, Raza A, Das AK, Azad Khan AK, Shrestha D, Qureshi MF, Md Fariduddin, Pathan MF, Jawad F, Bhattarai J, Tandon N, Somasundaram N, Katulanda P, Sahay R, Dhungel S, Bajaj S, Chowdhury S, Ghosh S, Madhu SV, Ahmed T, Bulughapitiya U. Place of sulfonylureas in the management of type 2 diabetes mellitus in South Asia: A consensus statement. Indian J Endocrinol Metab. 2015 Sep-Oct;19(5):577-96. doi: 10.4103/2230-8210.163171. Review.</citation>
    <PMID>26425465</PMID>
  </reference>
  <reference>
    <citation>Schopman JE, Simon AC, Hoefnagel SJ, Hoekstra JB, Scholten RJ, Holleman F. The incidence of mild and severe hypoglycaemia in patients with type 2 diabetes mellitus treated with sulfonylureas: a systematic review and meta-analysis. Diabetes Metab Res Rev. 2014 Jan;30(1):11-22. doi: 10.1002/dmrr.2470. Review.</citation>
    <PMID>24030920</PMID>
  </reference>
  <reference>
    <citation>Zhang Y, Si D, Chen X, Lin N, Guo Y, Zhou H, Zhong D. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics of gliclazide MR in Chinese subjects. Br J Clin Pharmacol. 2007 Jul;64(1):67-74. Epub 2007 Feb 12.</citation>
    <PMID>17298483</PMID>
  </reference>
  <reference>
    <citation>Shao H, Ren XM, Liu NF, Chen GM, Li WL, Zhai ZH, Wang DW. Influence of CYP2C9 and CYP2C19 genetic polymorphisms on pharmacokinetics and pharmacodynamics of gliclazide in healthy Chinese Han volunteers. J Clin Pharm Ther. 2010 Jun;35(3):351-60. doi: 10.1111/j.1365-2710.2009.01134.x.</citation>
    <PMID>20831536</PMID>
  </reference>
  <reference>
    <citation>Sun XM, Tan JC, Zhu Y, Lin L. Association between diabetes mellitus and gastroesophageal reflux disease: A meta-analysis. World J Gastroenterol. 2015 Mar 14;21(10):3085-92. doi: 10.3748/wjg.v21.i10.3085. Review.</citation>
    <PMID>25780309</PMID>
  </reference>
  <reference>
    <citation>Furuta T, Iwaki T, Umemura K. Influences of different proton pump inhibitors on the anti-platelet function of clopidogrel in relation to CYP2C19 genotypes. Br J Clin Pharmacol. 2010 Sep;70(3):383-92. doi: 10.1111/j.1365-2125.2010.03717.x.</citation>
    <PMID>20716239</PMID>
  </reference>
  <reference>
    <citation>Dujic T, Zhou K, Donnelly LA, Leese G, Palmer CNA, Pearson ER. Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylurea-induced hypoglycaemia: A GoDARTS Study. Diabetes Obes Metab. 2018 Jan;20(1):211-214. doi: 10.1111/dom.13046. Epub 2017 Aug 25.</citation>
    <PMID>28656666</PMID>
  </reference>
  <reference>
    <citation>Wedemeyer RS, Blume H. Pharmacokinetic drug interaction profiles of proton pump inhibitors: an update. Drug Saf. 2014 Apr;37(4):201-11. doi: 10.1007/s40264-014-0144-0. Review.</citation>
    <PMID>24550106</PMID>
  </reference>
  <reference>
    <citation>Semiz S, Dujic T, Ostanek B, Prnjavorac B, Bego T, Malenica M, Marc J, Causevic A. Analysis of CYP2C9*2, CYP2C19*2, and CYP2D6*4 polymorphisms in patients with type 2 diabetes mellitus. Bosn J Basic Med Sci. 2010 Nov;10(4):287-91.</citation>
    <PMID>21108610</PMID>
  </reference>
  <verification_date>July 2021</verification_date>
  <study_first_submitted>December 11, 2019</study_first_submitted>
  <study_first_submitted_qc>December 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">December 13, 2019</study_first_posted>
  <results_first_submitted>June 23, 2021</results_first_submitted>
  <results_first_submitted_qc>June 23, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">July 15, 2021</results_first_posted>
  <last_update_submitted>July 19, 2021</last_update_submitted>
  <last_update_submitted_qc>July 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Sarajevo</investigator_affiliation>
    <investigator_full_name>Tanja Dujic, PhD</investigator_full_name>
    <investigator_title>Associate Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 2</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gliclazide</mesh_term>
    <mesh_term>Omeprazole</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Data may be shared with researchers who provide a methodologically sound proposal.</ipd_description>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>September 14, 2018</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/48/NCT04198948/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>A total of 37 volunteers were recruited in the period between March 4th, 2019 and May 29th, 2019. On May 30th, 2019, volunteers were screened for CYP2C19 genotype status at the General Hospital in Sarajevo, B&amp;H.</recruitment_details>
      <pre_assignment_details>From 23 individuals, CYP2C19 EM/UM metabolisers, 16 were available for further health status assessment. One participant did not meet inclusion criteria and a total of 15 volunteers were randomised.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Omeprazole, Then Placebo</title>
          <description>Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive 20 mg of omeprazole alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive placebo under same conditions in a cross-over manner.&#xD;
Omeprazole: Omeprazole (20 mg) will be administered orally once daily for 5 days in one of the two treatment periods.&#xD;
Placebo oral tablet: Placebo will be administered orally once daily for 5 days in one of the two treatment periods.&#xD;
Gliclazide: Gliclazide (40 mg) will be administered orally once, concomitantly with omeprazole or placebo on day 5.</description>
        </group>
        <group group_id="P2">
          <title>Placebo, Then Omeprazole</title>
          <description>Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive placebo alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive omeprazole under same conditions in a cross-over manner.&#xD;
Omeprazole: Omeprazole (20 mg) will be administered orally once daily for 5 days in one of the two treatment periods.&#xD;
Placebo oral tablet: Placebo will be administered orally once daily for 5 days in one of the two treatment periods.&#xD;
Gliclazide: Gliclazide (40 mg) will be administered orally once, concomitantly with omeprazole or placebo on day 5.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Wash-out (10 Days)</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Period</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="7"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Omeprazole, Then Placebo</title>
          <description>Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive 20 mg of omeprazole alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive placebo under same conditions in a cross-over manner.&#xD;
Omeprazole: Omeprazole (20 mg) will be administered orally once daily for 5 days in one of the two treatment periods.&#xD;
Placebo oral tablet: Placebo will be administered orally once daily for 5 days in one of the two treatment periods.&#xD;
Gliclazide: Gliclazide (40 mg) will be administered orally once, concomitantly with omeprazole or placebo on day 5.</description>
        </group>
        <group group_id="B2">
          <title>Placebo, Then Omeprazole</title>
          <description>Healthy volunteers, CYP2C19 extensive/ultrarapid metabolisers, will receive placebo alone for 4 days, and concomitantly with single dose of gliclazide on day 5. After a wash-out period, they will receive omeprazole under same conditions in a cross-over manner.&#xD;
Omeprazole: Omeprazole (20 mg) will be administered orally once daily for 5 days in one of the two treatment periods.&#xD;
Placebo oral tablet: Placebo will be administered orally once daily for 5 days in one of the two treatment periods.&#xD;
Gliclazide: Gliclazide (40 mg) will be administered orally once, concomitantly with omeprazole or placebo on day 5.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="8"/>
            <count group_id="B3" value="15"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="22.9" spread="3.3"/>
                    <measurement group_id="B2" value="21.9" spread="2.2"/>
                    <measurement group_id="B3" value="22.3" spread="2.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Bosnia and Herzegovina</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="8"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kilograms</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="82.2" spread="12.5"/>
                    <measurement group_id="B2" value="75.7" spread="10.8"/>
                    <measurement group_id="B3" value="78.7" spread="11.7"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Gliclazide AUC</title>
        <description>Area under the concentration-time curve (AUC) up to the last concentration measured</description>
        <time_frame>24 hours</time_frame>
        <population>A total of 14 participants who completed both study periods were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Gliclazide + Omeprazole</title>
            <description>Participants received 20 mg of omeprazole alone for 4 days, and concomitantly with single dose of gliclazide on day 5.</description>
          </group>
          <group group_id="O2">
            <title>Gliclazide + Placebo</title>
            <description>Participants received placebo alone for 4 days, and concomitantly with single dose of gliclazide on day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Gliclazide AUC</title>
          <description>Area under the concentration-time curve (AUC) up to the last concentration measured</description>
          <population>A total of 14 participants who completed both study periods were included in the analysis.</population>
          <units>μgh/mL</units>
          <param>Geometric Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.73" lower_limit="2.81" upper_limit="4.93"/>
                    <measurement group_id="O2" value="3.29" lower_limit="2.65" upper_limit="4.09"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>The main evaluated outcome was systemic exposure to gliclazide, expressed as AUC(0-t). The geometric mean was calculated for gliclazide AUC(0-24). The ratio of the geometric means with 90% CIs was assessed by linear mixed models between the two treatment assignments: gliclazide and omeprazole co-administration to that of gliclazide and placebo. The obtained 90% CI was compared with the equivalence 0.8-1.25 range.</groups_desc>
            <non_inferiority_type>Equivalence</non_inferiority_type>
            <non_inferiority_desc>Sample size calculation was performed using SAS Proc Power procedure for equivalence test in 2x2 crossover design. For an equivalence range of 80-125%, the within-subject coefficient of variation for the AUC values for gliclazide of 7.8% based on previous PK studies, and expected test/reference geometric mean ratios between 87-115%, 14 volunteers (7 individuals per sequence) are required to show the lack of interaction with 85% power.</non_inferiority_desc>
            <param_type>Geometric least square mean ratio</param_type>
            <param_value>1.13</param_value>
            <ci_percent>90</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.86</ci_lower_limit>
            <ci_upper_limit>1.48</ci_upper_limit>
            <estimate_desc>The TOST (two one-sided test) test of equivalence showed that the geometric mean ratio and 90% CI for gliclazide AUC(0-24) between omeprazole and placebo phase was 1.13 (0.86-1.48), with upper confidence limit above the usual 1.25 boundary.</estimate_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Glucose</title>
        <description>Change in glucose concentration - incremental area under the glucose concentration-time curve from 0 to 12 h</description>
        <time_frame>12 hours</time_frame>
        <population>A total of 14 participants who completed both study periods were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Gliclazide + Omeprazole</title>
            <description>Participants received 20 mg of omeprazole alone for 4 days, and concomitantly with single dose of gliclazide on day 5.</description>
          </group>
          <group group_id="O2">
            <title>Gliclazide + Placebo</title>
            <description>Participants received placebo alone for 4 days, and concomitantly with single dose of gliclazide on day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Glucose</title>
          <description>Change in glucose concentration - incremental area under the glucose concentration-time curve from 0 to 12 h</description>
          <population>A total of 14 participants who completed both study periods were included in the analysis.</population>
          <units>mmol x h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.6" spread="4.3"/>
                    <measurement group_id="O2" value="4.0" spread="3.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.636</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin</title>
        <description>Change in insulin concentration - incremental area under the insulin concentration-time curve from 0 to 12 h</description>
        <time_frame>12 hours</time_frame>
        <population>A total of 14 participants who completed both study periods were included in the analysis.</population>
        <group_list>
          <group group_id="O1">
            <title>Gliclazide + Omeprazole</title>
            <description>Participants received 20 mg of omeprazole alone for 4 days, and concomitantly with single dose of gliclazide on day 5.</description>
          </group>
          <group group_id="O2">
            <title>Gliclazide + Placebo</title>
            <description>Participants received placebo alone for 4 days, and concomitantly with single dose of gliclazide on day 5.</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin</title>
          <description>Change in insulin concentration - incremental area under the insulin concentration-time curve from 0 to 12 h</description>
          <population>A total of 14 participants who completed both study periods were included in the analysis.</population>
          <units>mIU x h/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="14"/>
                <count group_id="O2" value="14"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="231.6" spread="93.8"/>
                    <measurement group_id="O2" value="265.9" spread="78.2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.055</p_value>
            <method>t-test, 2 sided</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Five days for each intervention.</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Gliclazide + Omeprazole</title>
          <description>Participants received 20 mg of omeprazole alone for 4 days, and concomitantly with single dose of gliclazide on day 5.</description>
        </group>
        <group group_id="E2">
          <title>Gliclazide + Placebo</title>
          <description>Participants received placebo alone for 4 days, and concomitantly with single dose of gliclazide on day 5.</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="15"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="15"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>Participants received half of the 80 mg gliclazide tablet registered as an immediate-release formulation in Bosnia and Herzegovina (Diprian®, Hemofarm d.o.o. Banja Luka, B&amp;H). However, the concentration-time profiles showed modified-release pattern and incomplete elimination within 24h; thus Cmax, tmax, t1/2, and AUC0-∞ could not be determined. The obtained PK profiles were used at the end for validation of physiologically based pharmacokinetic simulation of omeprazole-gliclazide interaction.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Associate Professor Tanja Dujic, PhD</name_or_title>
      <organization>University of Sarajevo</organization>
      <phone>+38733586194</phone>
      <email>tanja.dujic@ffsa.unsa.ba</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

